Bokf Na Boosts Stock Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Bokf Na grew its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 23.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 8,316 shares of the biopharmaceutical company’s stock after purchasing an additional 1,580 shares during the period. Bokf Na’s holdings in Ultragenyx Pharmaceutical were worth $342,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of RARE. Victory Capital Management Inc. raised its holdings in Ultragenyx Pharmaceutical by 44.6% during the 4th quarter. Victory Capital Management Inc. now owns 10,565 shares of the biopharmaceutical company’s stock valued at $505,000 after acquiring an additional 3,259 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in Ultragenyx Pharmaceutical by 18.9% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 471,825 shares of the biopharmaceutical company’s stock worth $22,563,000 after purchasing an additional 75,100 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in Ultragenyx Pharmaceutical by 13.6% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 6,325 shares of the biopharmaceutical company’s stock worth $303,000 after purchasing an additional 757 shares in the last quarter. Norges Bank purchased a new stake in Ultragenyx Pharmaceutical during the 4th quarter worth about $36,846,000. Finally, Clearbridge Investments LLC lifted its holdings in Ultragenyx Pharmaceutical by 3.9% during the 4th quarter. Clearbridge Investments LLC now owns 2,383,492 shares of the biopharmaceutical company’s stock worth $113,979,000 after purchasing an additional 89,922 shares in the last quarter. 97.67% of the stock is currently owned by hedge funds and other institutional investors.

Ultragenyx Pharmaceutical Trading Up 1.1 %

Shares of Ultragenyx Pharmaceutical stock opened at $59.36 on Tuesday. The firm has a market capitalization of $5.47 billion, a PE ratio of -7.39 and a beta of 0.56. The business’s 50-day moving average price is $50.83 and its 200-day moving average price is $46.25. Ultragenyx Pharmaceutical Inc. has a 12 month low of $31.52 and a 12 month high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($1.52) EPS for the quarter, beating the consensus estimate of ($1.64) by $0.12. The firm had revenue of $147.03 million for the quarter, compared to analyst estimates of $123.20 million. Ultragenyx Pharmaceutical had a negative return on equity of 266.02% and a negative net margin of 121.57%. The company’s revenue was up 35.7% on a year-over-year basis. During the same period in the prior year, the company earned ($2.25) EPS. As a group, analysts predict that Ultragenyx Pharmaceutical Inc. will post -6.24 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Emil D. Kakkis sold 20,000 shares of the stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $55.85, for a total transaction of $1,117,000.00. Following the transaction, the chief executive officer now directly owns 2,223,985 shares in the company, valued at approximately $124,209,562.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In the last three months, insiders have sold 40,675 shares of company stock worth $2,149,446. 5.80% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of analysts recently issued reports on the company. Cantor Fitzgerald reissued an “overweight” rating and set a $116.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Monday. Wells Fargo & Company increased their price objective on Ultragenyx Pharmaceutical from $72.00 to $75.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. Wedbush increased their price objective on Ultragenyx Pharmaceutical from $43.00 to $46.00 and gave the stock a “neutral” rating in a report on Friday, August 2nd. The Goldman Sachs Group increased their price objective on Ultragenyx Pharmaceutical from $67.00 to $76.00 and gave the stock a “buy” rating in a report on Friday, August 2nd. Finally, Bank of America dropped their price objective on Ultragenyx Pharmaceutical from $83.00 to $76.00 and set a “buy” rating on the stock in a report on Friday, May 31st. Two investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $87.43.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.